What happened to R & D? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

What happened to R & D?

Aug 8, 2000

Around nine months back the market was agog with rumours of Indian companies doing path breaking research. Ranbaxy developed a new single dosage delivery mechanism for ciprofloxacin, which it sold to Bayer. Dr. Reddy’s licensed two anti–diabetes molecules to Novo Nordisk and received its first milestone payment. Cipla was reported to be working on new chemical entities (NCEs). Nine months later the aura seems to have worn off. Cipla is yet to announce any pathbreaking result. The management of Dr Reddy’s has been unduly cagey about reports of the second milestone payment being received from Novo Nordisk.

Ranbaxy is also supposed to be receiving a second milestone payment for its deal with Bayer in the third quarter. It’s high time the company actually did! The stock has almost halved over the last nine months and the first half performance of the company has been nothing to write home about. Ranbaxy was also supposed to be working on a BPH (benign prostrate hyperplasia) compound, but the company has yet to announce the progress on the research.

The world over pharma companies make regular disclosures about the stage at which each molecule is (i.e whether the molecule has completed pre clinical trials or phase I or phase II of clinical trials). Indian companies are still very secretive about these issues.

Equitymaster requests your view! Post a comment on "What happened to R & D?". Click here!


More Views on News

Dr Reddy's New Covid-19 Treatment Option Puts Stock in Focus (Views On News)

May 24, 2021

With the second wave pushing up sales of medicines, Indian pharma companies are likely to see traction in their volumes.

Dr Reddy's Lab Shares Fall As Earnings Miss Estimates. What Next? (Views On News)

May 14, 2021

The company's board recommended a final dividend of Rs 25 for financial year 2020-21.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 6, 2021 03:36 PM


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks